Drug intelligence / Profile preview

R112

Development stage: Phase 2
Lead developer: Rigel Pharmaceuticals
Modality: Small Molecules
Administration: Intranasal

Overview

R926112 (also known as R112) is an investigational small molecule drug developed as a nasal spray for the treatment of seasonal allergic rhinitis. It acts as a mast cell inhibitor and functions primarily by inhibiting spleen tyrosine kinase (Syk), which plays a key role in immune cell signaling involved in allergic responses. The drug was evaluated in clinical trials for its efficacy and safety compared to placebo and beclomethasone dipropionate (an established steroid treatment). Development was led by Rigel Pharmaceuticals, with studies reaching at least Phase 2 for seasonal allergic rhinitis.

Targets

SYK (Spleen Tyrosine Kinase)

Beyond the preview

Go deeper on R112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on R112.

Explore the full profile